Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports

Open Access 30-09-2024 | Hypertriglyceridemia | Review

Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia

Authors: Charles A. Gagnon, Ambika P. Ashraf

Published in: Current Atherosclerosis Reports

Login to get access

Abstract

Purpose of Review

To provide a comprehensive overview of hypertriglyceridemia (HTG) in youth, identifying gaps in categorizing triglyceride (TG) levels and management strategies, and exploring new therapies for TG reduction.

Recent Findings

Non-fasting TG levels as important cardiovascular (CV) risk indicators, with HTG's pathophysiology involving genetic and secondary factors affecting TG metabolism. Emerging treatments, including those affecting the lipoprotein lipase complex and inhibiting proteins like apoC3 and ANGPTL3, show promise.

Summary

The review highlights the need for specific management approaches for youth, the significance of non-fasting TG levels, and the potential of new therapies in reducing CV and pancreatitis risks, advocating for further research on these treatments' efficacy and safety.
Literature
1.
Valaiyapathi B, Sunil B, Ashraf AP. Approach to hypertriglyceridemia in the pediatric population. Pediatr Rev. 2017;38(9):424–34.PubMedCrossRef
2.
FOR EPOIG, CHILDREN RRI. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213.
3.
Centers for Disease C, Prevention. Prevalence of abnormal lipid levels among youths --- United States, 1999–2006. MMWR Morb Mortal Wkly Rep. 2010;59(2):29–33.
4.
Dhuper S, Sakowitz S, Daniels J, Buddhe S, Cohen HW. Association of lipid abnormalities with measures and severity of adiposity and insulin resistance among overweight children and adolescents. J Clin Hypertens (Greenwich). 2009;11(10):594–600.PubMedCrossRef
5.
Korsten-Reck U, Kromeyer-Hauschild K, Korsten K, Baumstark MW, Dickhuth HH, Berg A. Frequency of secondary dyslipidemia in obese children. Vasc Health Risk Manag. 2008;4(5):1089–94.PubMedCrossRefPubMedCentral
6.
Bell LM, Curran JA, Byrne S, Roby H, Suriano K, Jones TW, Davis EA. High incidence of obesity co-morbidities in young children: a cross-sectional study. J Paediatr Child Health. 2011;47(12):911–7.PubMedCrossRef
7.
Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655–66.PubMedCrossRef
8.
9.
Simons-Linares CR, Jang S, Sanaka M, Bhatt A, Lopez R, Vargo J, et al. The triad of diabetes ketoacidosis, hypertriglyceridemia and acute pancreatitis How does it affect mortality and morbidity?: A 10-year analysis of the National Inpatient Sample. Medicine (Baltimore). 2019;98(7):e14378.PubMedCrossRef
10.
11.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9(2):129–69.PubMedCrossRef
12.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–209.PubMedCrossRef
13.
Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–89.PubMedCrossRefPubMedCentral
14.
Frontini MG, Srinivasan SR, Xu J, Tang R, Bond MG, Berenson GS. Usefulness of childhood non–high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: The Bogalusa Heart Study. Pediatrics. 2008;121(5):924–9.PubMedCrossRef
15.
Daniels SR, Greer FR, Nutrition Co. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208.PubMedCrossRef
16.
De Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation. 2019;139(13):e603–34.PubMedCrossRef
17.
Savorani F, Kristensen M, Larsen FH, Astrup A, Engelsen SB. High throughput prediction of chylomicron triglycerides in human plasma by nuclear magnetic resonance and chemometrics. Nutr Metab. 2010;7:1–8.CrossRef
18.
Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. The Lancet. 2014;384(9943):626–35.CrossRef
19.
Steiner MJ, Skinner AC, Perrin EM. Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study. Pediatrics. 2011;128(3):463–70.PubMedCrossRefPubMedCentral
20.
Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem. 2011;57(3):482–9.PubMedCrossRef
21.
Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172(22):1707–10.PubMedCrossRef
22.
Lindman AS, Veierod MB, Tverdal A, Pedersen JI, Selmer R. Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur J Epidemiol. 2010;25(11):789–98.PubMedCrossRefPubMedCentral
23.
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–16.PubMedCrossRef
24.
Iso H, Imano H, Yamagishi K, Ohira T, Cui R, Noda H, et al. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis. 2014;237(1):361–8.PubMedCrossRef
25.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.PubMedCrossRef
26.
Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142–52.PubMedCrossRef
27.
Nordestgaard BG, Freiberg JJ. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol. 2011;9(3):281–6.PubMedCrossRef
28.
Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–36.PubMedCrossRef
29.
Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. J Am Coll Cardiol. 2017;70(13):1637–46.PubMedCrossRef
30.
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333.PubMedCrossRef
31.
Kolovou GD, Watts GF, Mikhailidis DP, Perez-Martinez P, Mora S, Bilianou H, et al. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement. Main Text Curr Vasc Pharmacol. 2019;17(5):498–514.PubMedCrossRef
32.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.PubMedCrossRef
33.
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–8.PubMedCrossRef
34.
Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52.PubMedCrossRefPubMedCentral
35.
Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707–13.PubMedCrossRefPubMedCentral
36.
Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298–309.PubMedCrossRef
37.
Marston NA, Giugliano RP, Im K, Silverman MG, O’Donoghue ML, Wiviott SD, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140(16):1308–17.PubMedCrossRefPubMedCentral
38.
Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118(4):547–63.PubMedCrossRef
39.
Krauss RM. Dense low density lipoproteins and coronary artery disease. Am J Cardiol. 1995;75(6):53B-B57.PubMedCrossRef
40.
41.
Tullu MS, Advirkar AV, Ghildiyal RG, Tambe S. Familial hypertriglyceridemia. Indian J Pediatr. 2008;75(12):1257–8.PubMedCrossRef
42.
Brouwers MC, van Greevenbroek MM, Stehouwer CD, de Graaf J, Stalenhoef AF. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol. 2012;8(6):352–62.PubMedCrossRef
43.
Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia–clinical and pathophysiological features. S Afr Med J. 2002;92(11):892–7.PubMed
44.
Ashraf AP, Hurst AC, Garg A. Extreme hypertriglyceridemia, pseudohyponatremia, and pseudoacidosis in a neonate with lipoprotein lipase deficiency due to segmental uniparental disomy. J Clin Lipidol. 2017;11(3):757–62.PubMedCrossRef
45.
Ashraf AP, Miyashita K, Nakajima K, Murakami M, Hegele RA, Ploug M, et al. Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. J Clin Lipidol. 2020;14(2):197–200.PubMedCrossRefPubMedCentral
46.
Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960–93.PubMedCrossRef
47.
Brahm AJ, Hegele RA. Chylomicronaemia—current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352–62.PubMedCrossRef
48.
McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20(8):1998–2004.PubMedCrossRef
49.
Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338(23):1650–6.PubMedCrossRef
50.
Wu F, Juonala M, Jacobs DR Jr, Daniels SR, Kahonen M, Woo JG, et al. Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events. Circulation. 2024;149(3):217–26.PubMedCrossRef
51.
Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Pena Genao E, Guzman E, Kostara CE. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics (Basel). 2023;13(5):929.PubMedCrossRef
52.
Elkins C, Friedrich D. Hypertriglyceridemia: A review of the evidence. Nurse Pract. 2018;43(10):22–9.PubMedCrossRef
53.
54.
Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta. 1981;112(1):43–53.CrossRef
55.
Becker M, Staab D, Von Bergman K. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics. 1992;89(1):138–42.PubMedCrossRef
56.
Smalley CM, Goldberg SJ. A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol. 2008;2(2):106–11.PubMedCrossRef
57.
Gidding SS, Prospero C, Hossain J, Zappalla F, Balagopal PB, Falkner B, Kwiterovich P. A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. J Pediatr. 2014;165(3):497-503 e2.PubMedCrossRefPubMedCentral
58.
de Ferranti SD, Milliren CE, Denhoff ER, Steltz SK, Selamet Tierney ES, Feldman HA, Osganian SK. Using high-dose omega-3 fatty acid supplements to lower triglyceride levels in 10- to 19-year-olds. Clin Pediatr (Phila). 2014;53(5):428–38.PubMedCrossRef
59.
Valaiyapathi B, Ashraf AP. Hospital management of severe hypertriglyceridemia in children. Curr Pediatr Rev. 2017;13(4):225–31.PubMedCrossRef
60.
Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019;381(6):531–42.PubMedCrossRef
61.
Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(5):264–75.PubMedCrossRef
62.
den Hollander B, Brands MM, Nijhuis IJM, Doude van Troostwijk L, van Essen P, Hofsteenge AH, et al. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen. Mol Genet Metab. 2024;142(1):108347.
63.
Esan O, Wierzbicki AS. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy. Drug Des Devel Ther. 2020;14:2623–36.PubMedCrossRefPubMedCentral
64.
Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401–12.PubMedCrossRefPubMedCentral
65.
66.
Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211–21.PubMedCrossRefPubMedCentral
67.
Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729–37.PubMedCrossRefPubMedCentral
68.
69.
Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377–86.PubMedCrossRefPubMedCentral
70.
Watts GF, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia. Circulation. 2020;142(Suppl_3):15751.CrossRef
71.
Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142–9.PubMedCrossRefPubMedCentral
Metadata
Title
Beyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia
Authors
Charles A. Gagnon
Ambika P. Ashraf
Publication date
30-09-2024
Publisher
Springer US
Published in
Current Atherosclerosis Reports
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-024-01237-z

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits